Inside USP: Annual Scientific Meeting Recap - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Inside USP: Annual Scientific Meeting Recap
Representatives from 17 nations sit down to decide upon standards-setting initiatives.


Pharmaceutical Technology




Although the phrase "annual scientific meeting"may have a stilted connotation in the United States, the USPharmacopeia (USP)has taken the yearly event to a new level by going international. For several years, the organization has developed US-based annual scientific meetings, including its recent September meeting in Tampa, but USP now plans to hold annual scientific meetings abroad at its various global sites. Meetings already were held in India last February, and in September, the organization held a meeting during the opening of its Shanghai, China, office.

In addition, USP's Board of Trustees recently authorized the establishment of a USP site in São Paulo, Brazil, where a regional annual scientific meeting is tentatively scheduled for next summer. USPalso plans to meet in the Middle East next fall.

Although USPis extending its global presence, its largest audience is still in the US. Approximately 300 delegates attended the 2007 scientific meeting in Tampa. Delegates represented US and international pharmaceutical companies, regulatory bodies such as the US Food and Drug Administration and Council of Europe, as well as regulatory and industry organizations in Brazil, Mexico, Japan, the United Arab Emirates, and the United Kingdom. Stakeholders represented 17 nations.

The following provides an overview of the 2007 meeting, including its three most popular tracks.

Topics and tracks

This year's two-day meeting was unique compared with past years because the number of speakers in each session was limited to allow more detailed presentations and longer discussion sessions. Participants could customize their agenda by choosing among five tracks: Quality of Manufactured Medicines—Monographs and Reference Standards; Quality of Manufactured Medicines—General Chapters and Performance Testing; Quality of Manufactured Medicines—Biologics and Biotechnology; Quality of Care; and International Health.

The opening plenary included a number of USP organizational reports. Among the most noteworthy were:the board's authorization of USP's acquisition and publication from March 2008 of Food Chemicals Codex (FCC), and, as noted, the launch of a site in Brazil; the Council of Experts' ongoing work to revise the General Notices of the United States Pharmacopeia–National Formulary and FCC; and a stakeholder report that commented on revisions to "Residual Solvents" <467>, monograph redesign, harmonization, and salt nomenclature, among other topics.

Two plenary speakers addressed current topics in biologics and genomics. Both expressed confidence that advances in proteomics and genomics may positively affect public health. They, however, were also concerned about overly optimistic projections and the absence of standards as biotechnology products and diagnostics move beyond the laboratory into public commerce.

The second day's plenary consisted of presentations by USP's executive vice- president–chief executive officer(EVP–CEO), chief science officer, and chief reference materials officer. The EVP-CEO spoke about core scientific initiatives at USP, particularly the quality of manufactured and compounded foods and medicines and how manufacturers can demonstrate that their products are equivalent to approved products. Because FCC is not an official compendium of the US, establishing standards for food ingredients remains a challenge. One solution would be to move FCC to official status in US regulations.

The chief science officer commented in detail about USP's continuing work on "Residual Solvents" <467>, "Heavy Metals" <231> (bearing in mind that by one estimate the periodic table contains approximately 72 metals of pharmaceutical interest), flexible monographs, and related monograph-related topics. Finally, the chief reference materials officer highlighted the evolution of standards and standards-setting procedures beginning with putative anthropomorphic units (the supposed length of a monarch's foot) to crude physical marks (e.g., two spikes in a stick, used to make scratch marks that represented a meter) to vibrational units (the wavelength of an elemental spectrum) to current concepts about the speed of light in a vacuum. A unifying theme among the speakers was the need for metrologically informed standards that are developed by an international public process of review and comment.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
19%
To all process for new products only
14%
To select process for new products only
24%
To select processes for both new and legacy products
19%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here